571 related articles for article (PubMed ID: 20405927)
1. Structure-based discovery of A2A adenosine receptor ligands.
Carlsson J; Yoo L; Gao ZG; Irwin JJ; Shoichet BK; Jacobson KA
J Med Chem; 2010 May; 53(9):3748-55. PubMed ID: 20405927
[TBL] [Abstract][Full Text] [Related]
2. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
[TBL] [Abstract][Full Text] [Related]
3. Docking Finds GPCR Ligands in Dark Chemical Matter.
Ballante F; Rudling A; Zeifman A; Luttens A; Vo DD; Irwin JJ; Kihlberg J; Brea J; Loza MI; Carlsson J
J Med Chem; 2020 Jan; 63(2):613-620. PubMed ID: 31846328
[TBL] [Abstract][Full Text] [Related]
4. Structure-based discovery of beta2-adrenergic receptor ligands.
Kolb P; Rosenbaum DM; Irwin JJ; Fung JJ; Kobilka BK; Shoichet BK
Proc Natl Acad Sci U S A; 2009 Apr; 106(16):6843-8. PubMed ID: 19342484
[TBL] [Abstract][Full Text] [Related]
5. Molecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.
Rodríguez D; Gao ZG; Moss SM; Jacobson KA; Carlsson J
J Chem Inf Model; 2015 Mar; 55(3):550-63. PubMed ID: 25625646
[TBL] [Abstract][Full Text] [Related]
6. Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.
Jacobson KA
J Med Chem; 2013 May; 56(10):3749-67. PubMed ID: 23597047
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A2A receptor as a drug discovery target.
de Lera Ruiz M; Lim YH; Zheng J
J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
[TBL] [Abstract][Full Text] [Related]
8. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.
Katritch V; Jaakola VP; Lane JR; Lin J; Ijzerman AP; Yeager M; Kufareva I; Stevens RC; Abagyan R
J Med Chem; 2010 Feb; 53(4):1799-809. PubMed ID: 20095623
[TBL] [Abstract][Full Text] [Related]
9. Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: the human A₂A adenosine receptor as a key study.
Sabbadin D; Ciancetta A; Moro S
J Chem Inf Model; 2014 Jan; 54(1):169-83. PubMed ID: 24359090
[TBL] [Abstract][Full Text] [Related]
10. Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries.
Ranganathan A; Heine P; Rudling A; Plückthun A; Kummer L; Carlsson J
ACS Chem Biol; 2017 Mar; 12(3):735-745. PubMed ID: 28032980
[TBL] [Abstract][Full Text] [Related]
11. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.
Tosh DK; Phan K; Gao ZG; Gakh AA; Xu F; Deflorian F; Abagyan R; Stevens RC; Jacobson KA; Katritch V
J Med Chem; 2012 May; 55(9):4297-308. PubMed ID: 22486652
[TBL] [Abstract][Full Text] [Related]
12. A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.
Cristalli G; Lambertucci C; Marucci G; Volpini R; Dal Ben D
Curr Pharm Des; 2008; 14(15):1525-52. PubMed ID: 18537675
[TBL] [Abstract][Full Text] [Related]
13. Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.
Załuski M; Schabikowski J; Schlenk M; Olejarz-Maciej A; Kubas B; Karcz T; Kuder K; Latacz G; Zygmunt M; Synak D; Hinz S; Müller CE; Kieć-Kononowicz K
Bioorg Med Chem; 2019 Apr; 27(7):1195-1210. PubMed ID: 30808606
[TBL] [Abstract][Full Text] [Related]
14. In search of novel ligands using a structure-based approach: a case study on the adenosine A
Lenselink EB; Beuming T; van Veen C; Massink A; Sherman W; van Vlijmen HW; IJzerman AP
J Comput Aided Mol Des; 2016 Oct; 30(10):863-874. PubMed ID: 27629350
[TBL] [Abstract][Full Text] [Related]
15. Could the presence of sodium ion influence the accuracy and precision of the ligand-posing in the human A
Margiotta E; Deganutti G; Moro S
J Comput Aided Mol Des; 2018 Dec; 32(12):1337-1346. PubMed ID: 30361971
[TBL] [Abstract][Full Text] [Related]
16. Substructure-based virtual screening for adenosine A2A receptor ligands.
van der Horst E; van der Pijl R; Mulder-Krieger T; Bender A; Ijzerman AP
ChemMedChem; 2011 Dec; 6(12):2302-11. PubMed ID: 22021213
[TBL] [Abstract][Full Text] [Related]
17. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A(2A) antagonistic properties of selected C8-substituted xanthines.
Van der Walt MM; Terre'Blanche G; Petzer A; Lourens AC; Petzer JP
Bioorg Chem; 2013 Aug; 49():49-58. PubMed ID: 23892098
[TBL] [Abstract][Full Text] [Related]
19. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
Fan F; Toledo Warshaviak D; Hamadeh HK; Dunn RT
PLoS One; 2019; 14(1):e0204378. PubMed ID: 30605479
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A
Zhang M; Fan S; Zhou X; Xie F; Li S; Zhong W
Eur J Med Chem; 2019 Oct; 179():310-324. PubMed ID: 31255928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
